David Pook

6.9k total citations
60 papers, 976 citations indexed

About

David Pook is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, David Pook has authored 60 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in David Pook's work include Prostate Cancer Treatment and Research (33 papers), Renal cell carcinoma treatment (17 papers) and Cancer Immunotherapy and Biomarkers (17 papers). David Pook is often cited by papers focused on Prostate Cancer Treatment and Research (33 papers), Renal cell carcinoma treatment (17 papers) and Cancer Immunotherapy and Biomarkers (17 papers). David Pook collaborates with scholars based in Australia, United States and Canada. David Pook's co-authors include Gail P. Risbridger, Renea A. Taylor, Mark Frydenberg, Roxanne Toivanen, Mitchell G. Lawrence, Hong Wang, Stuart J. Ellem, Melissa Papargiris, Joan Carles and Birunthi Niranjan and has published in prestigious journals such as Journal of Clinical Oncology, Biomaterials and Cancer Research.

In The Last Decade

David Pook

52 papers receiving 962 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Pook Australia	14	631	454	309	231	217	60	976
Zishuo I. Hu United States	11	378 0.6×	748 1.6×	217 0.7×	197 0.9×	415 1.9×	12	1.2k
Adam Cooper Australia	16	257 0.4×	669 1.5×	318 1.0×	292 1.3×	303 1.4×	38	1.1k
Muyun Peng China	11	270 0.4×	333 0.7×	217 0.7×	145 0.6×	214 1.0×	34	710
Fabrizio Tabbò Italy	17	413 0.7×	560 1.2×	421 1.4×	144 0.6×	265 1.2×	51	1.2k
Christine Böger Germany	16	479 0.8×	708 1.6×	232 0.8×	221 1.0×	146 0.7×	23	1.2k
Ecaterina E. Dumbrava United States	17	218 0.3×	647 1.4×	379 1.2×	185 0.8×	194 0.9×	115	1.0k
Els Van Nieuwenhuysen Belgium	20	193 0.3×	559 1.2×	372 1.2×	180 0.8×	325 1.5×	99	1.3k
Analía Azaro Spain	18	295 0.5×	557 1.2×	569 1.8×	152 0.7×	198 0.9×	56	1.1k
Alexandra S. Zimmer United States	13	344 0.5×	815 1.8×	365 1.2×	192 0.8×	110 0.5×	24	1.1k
Si-Pei Wu China	13	659 1.0×	941 2.1×	544 1.8×	300 1.3×	386 1.8×	23	1.5k

Countries citing papers authored by David Pook

Since Specialization

Citations

This map shows the geographic impact of David Pook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Pook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Pook more than expected).

Fields of papers citing papers by David Pook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Pook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Pook. The network helps show where David Pook may publish in the future.

Co-authorship network of co-authors of David Pook

This figure shows the co-authorship network connecting the top 25 collaborators of David Pook. A scholar is included among the top collaborators of David Pook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Pook. David Pook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pook, David, et al.. (2025). Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer. BJUI Compass. 6(4). e70012–e70012.

Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).

Tran, Ben, Kevin D. Courtney, Alexandra Sokolova, et al.. (2025). A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.. Journal of Clinical Oncology. 43(5_suppl).

Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.

Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations

Kelly, William Kevin, Leonard J. Appleman, C-C. Lin, et al.. (2024). 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study. Annals of Oncology. 35. S963–S964. 1 indexed citations

Danila, Daniel C., C-C. Lin, Jia-Lin Lee, et al.. (2024). 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig. Annals of Oncology. 35. S971–S972. 1 indexed citations

Kelly, William Kevin, Daniel C. Danila, C-C. Lin, et al.. (2023). 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 34. S1576–S1576. 1 indexed citations

Gedye, Craig, Carole A. Harris, Martin R. Stockler, et al.. (2023). 1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Annals of Oncology. 34. S1014–S1014.

10.

Horvath, Lisa G., Ian D. Davis, Andrew Martin, et al.. (2023). 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Annals of Oncology. 34. S968–S969. 2 indexed citations

11.

Graff, Julie N., Mauricio Burotto, Peter C.C. Fong, et al.. (2023). 1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study. Annals of Oncology. 34. S957–S957. 13 indexed citations

12.

Albigès, Laurence, Howard Gurney, Vagif Atduev, et al.. (2023). Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet Oncology. 24(8). 881–891. 73 indexed citations

13.

Lawrence, Mitchell G., Laura H. Porter, David Pook, et al.. (2021). CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics. 20(11). 2140–2150. 17 indexed citations

14.

Choueiri, Toni K., Thomas Powles, Mauricio Burotto, et al.. (2020). 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology. 31. S1159–S1159. 85 indexed citations

15.

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations

16.

Kwan, Edmond M., Heidi Fettke, Maria Docanto, et al.. (2019). Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 7(1). 63–70. 11 indexed citations

17.

Porter, Laura H., Mitchell G. Lawrence, Shahneen Sandhu, et al.. (2019). PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer. 2 indexed citations

18.

Powles, T.B., Bernard Escudier, Paul de Souza, et al.. (2016). Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial. Annals of Oncology. 27. vi284–vi284. 1 indexed citations

19.

Rajarubendra, Nieroshan, David Pook, Mark Frydenberg, & Sree Appu. (2014). Rare synchronous metastases of renal cell carcinoma. Urology Annals. 6(2). 157–157. 3 indexed citations

20.

Lawrence, Mitchell G., Renea A. Taylor, Roxanne Toivanen, et al.. (2013). A preclinical xenograft model of prostate cancer using human tumors. Nature Protocols. 8(5). 836–848. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact